Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022
Abstract
6511 Background: In 2024, the US Food & Drug Administration will require drug sponsors to implement plans to improve racial/ethnic diversity in clinical trials. While minoritized populations are less likely to participate in cancer trials, it is unknown whether social determinants of health (SDOH) explain these inequities. Here we identified SDOH factors that contribute to racial/ethnic inequities in clinical trial participation among patients with 22 solid and blood cancers. Methods: This retrospective study used the nationwide Flatiron Health electronic health record-derived de-identified database of adult patients with cancer (2011-2022). Area-level SDOH ( e.g., predominant race/ethnicity [proxy for segregation]) contextualizing where patients live were defined using the American Community Survey tract data. Patients were followed from cancer-specific diagnosis to clinical study drug receipt (proxy for trial participation), death, or last recorded activity. Associations of race/ethnicity and SDOH factors on trial participation were assessed using Cox proportional hazards models adjusted for clinical factors (diagnosis year, age, sex, performance status, stage, and cancer type). To elucidate which SDOH explain racial/ethnic inequities, mediation analysis was performed using nonlinear multiple additive regression trees models. Results: This study included 233,556 patients (median age: 68 years, 50.0% women; 65.6% non-Latinx [NL] White, 8.5% NL Black, 5.0% Latinx). Black and…
Read the paper
Related studies
- A Survey on Knowledge Graphs: Representation, Acquisition, and Applications
- Toxicity of nanomaterials
- The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies
- Halogen bonding (X‐bonding): A biological perspective
- Biofilm formation at the air–liquid interface by the Pseudomonas fluorescens SBW25 wrinkly spreader requires an acetylated form of cellulose
- Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.